Zepbound (tirzepatide) is a GLP-1/GIP medication, manufactured by Elli Lilly, approved for weight management and weight loss. As usage expands, some patients have reported severe and sometimes life-altering complications — including gastroparesis (stomach paralysis), intestinal obstruction, pancreatitis, gallbladder disease, dehydration-related kidney injury, and long-term digestive impairment. Many affected individuals are now exploring potential legal claims and filing Zepbound lawsuits.
Zepbound was approved by the FDA. It is a weekly injectable rug (1x weekly) for weight management in people over 18 who are obese or just overweight. Zepbound contains the same Active Ingredient, Tirzepatide, which is in Mounjaro. Elli Lilly for marketing purposes brands Zepbound for weight management and not for type two diabetes. Zepbound is effective because it targets GIP and GLP-1 receptors to lessen appetite and help with the feeling of satiety. It is recommended that Zepbound be utilized with diet and exercise. It has been very effective in providing weight loss results in patients. Zepbound lawsuit settlement amounts will not be known for years.
There are Zepbound lawsuits that are in essence product liability litigation related to allegations that Eli Lilly failed to warn about the side effects of the medication. This page outlines the injuries most often associated with Zepbound-related claims, how eligibility is evaluated, and what evidence typically matters during case review.
Two Zepbound & GLP-1 MDLs in Federal Court
As of March 8, 2026, over 3,300 lawsuits have been filed against Novo Nordisk and Eli Lilly in the two Federal MDLs alleging severe and often debilitating complications associated with the medications. Many of these lawsuits are Zepbound lawsuits. The primary Zepbound (GLP-1) lawsuit is: “In Re Glucagonlike Peptide-1 Receptor Agonists Products Liability Litigation”, MDL No. 3094. This is a federal Multi District Litigation.
A victim can file a Zepbound lawsuit in that ongoing Multidistrict Litigation (MDL) (MDL 3094) located in the Eastern District of Pennsylvania. The central Allegations is that Eli Lilly did not properly warn victims and their physicians about the dangers and risks of severe gastrointestinal side effects. The focus of the lawsuits is on severe side effects, such as: Gastroparesis (stomach paralysis), Intestinal blockages or ileus, Deep vein thrombosis (DVT) and gallbladder disease.
A 2nd MDL for Naion and vision loss lawsuits has also been established. The U.S. Judicial Panel on Multidistrict Litigation, which oversees all mass tort litigation in federal court determined that the GLP-1 and ZEPBOUND claims related to vision loss will be litigated in a separate federal court multi-district litigation (MDL) than the GLP-1 digestive complications MDL (MDL 3094). The new vision loss MDL is entitled “MDL 3163 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation”
Both the Zepbound and GLP-1 vision loss MDL (MDL 3163) and the Zepbound- GLP-1 digestive side effects MDL (MDL 3094) will be pending in Pennsylvania federal court before Judge Marston.
As of March of 2026, over 3,300 lawsuits related to multiple GLP-1 drugs have been pending in the two federal MDLs. For their part, Eli Lilly and Novo Nordisk have filed motions to dismiss numerous lawsuits. Nonetheless, litigation is ongoing.
Two Zepbound / GLP-1 Litigations in NJ State Courts
There are now two Multi County Litigations in New Jersey State Court. The New Jersey Supreme Court ruled that litigation filed in NEW JERSEY STATE COURTS related to GLP-1 and Zepbound vision loss will proceed separately from the New Jersey GLP-1 (Zepbound) litigation concerning stomach paralysis and assorted gastrointestinal side effects. The NAION litigation will be part of a separate MCL in Bergen County NJ presided by Superior Court Judge Gregg A. Padovano. Justice Padovano will also be the presiding judge of the gastroparesis / digestion litigation in New Jersey State Courts.
Zepbound approved to treat Sleep Apnea
The Food and Drug Administration (FDA) greenlighted Zepbound in December 2024 to be used to treat moderate-to-severe obstructive sleep apnea (OSA) in people over 18 who are overweight and obese by lowering body weight. Less body weight lowers the amount of fat in the neck area and in the upper airway, lowering interruptions breathing while sleeping. It is Administered in a Self-administered manner via a jab, usually in the stomach or thigh area.
Why Zepbound Lawsuits Are Emerging
Claim reviews and investigations commonly focus on allegations that:
- patients were not clearly warned about the risk of severe GI motility disorders
- nausea and vomiting were presented as “temporary” even when they can become chronic
- rapid weight loss and prolonged appetite suppression contributed to gallbladder complications
- dehydration from vomiting contributed to kidney injury
- long-term safety outcomes for broad population use remain incomplete
Many patients state they used Zepbound as prescribed but experienced unexpectedly severe outcomes requiring emergency treatment.
Injuries Commonly Reported in Zepbound Claims
Gastroparesis (Stomach Paralysis)
A leading injury in GLP-1 legal screenings.
Reported symptoms include:
- chronic nausea
- vomiting undigested food
- extreme fullness after small meals
- inability to tolerate solid foods
- motility testing confirming delayed emptying
- long-term dietary restriction and disability
➡️ Legal hub: Gastroparesis
Intestinal Obstruction & Severe Motility Disorders
Some cases involve severe slowing throughout the digestive tract, resulting in:
- inability to pass stool or gas
- abdominal swelling and pain
- severe constipation or bowel shutdown
- hospitalization and imaging
- surgical evaluation or intervention
➡️ Legal hub: Intestinal Obstruction
Pancreatitis
Reported complications include:
- intense upper abdominal pain radiating to the back
- vomiting, fever
- elevated pancreatic enzymes
- hospitalization and IV therapy
- recurrence or chronic pancreatic impairment in some cases
➡️ Legal hub: Pancreatitis
Kidney Injury & Kidney Failure (Often Dehydration-Driven)
Kidney injury may develop after:
- prolonged vomiting
- persistent dehydration
- electrolyte imbalance
- pancreatitis complications
Possible findings:
- AKI
- reduced eGFR
- elevated creatinine
- hospitalization for IV fluids
- dialysis (severe cases)
➡️ Legal hub: Kidney Failure
Gallbladder Disease & Removal
Because Zepbound can cause rapid, significant weight loss, reported gallbladder events include:
- gallstones
- gallbladder inflammation
- bile duct obstruction
- gallbladder removal surgery
- persistent digestive symptoms after surgery
➡️ Legal hub: Gallbladder Removal
Patterns Seen in Zepbound Case Evaluations
Legal screenings often identify patterns such as:
- worsening vomiting after dose escalation
- extended inability to tolerate normal meals
- repeated ER visits for dehydration
- documented motility dysfunction
- measurable kidney decline following vomiting episodes
- gallbladder crises after rapid weight loss
- symptoms persisting after discontinuation
Objective documentation (imaging, labs, motility testing) frequently strengthens claim eligibility.
Who May Qualify for a Zepbound Injury Claim
You may qualify if:
- you used Zepbound, AND
- you developed a serious complication requiring treatment, AND
- you experienced long-term harm or significant disruption to daily life
Common potentially qualifying diagnoses include:
- confirmed gastroparesis or delayed gastric emptying
- intestinal obstruction or severe motility disorder
- pancreatitis
- kidney injury or kidney failure
- gallbladder disease or gallbladder removal
- chronic vomiting with hospitalization
- long-term nutritional impairment or disability
If your condition impacted work, independence, or normal eating, a case review may be warranted.
Evidence That Strengthens Zepbound Claims
Strong claim reviews typically include:
- GI testing (gastric emptying scan, motility studies)
- abdominal imaging (CT/MRI/ultrasound)
- pancreatic enzyme labs (lipase/amylase)
- kidney function labs (creatinine, eGFR, BUN)
- gallbladder imaging and surgical notes
- ER/hospital admission and discharge records
- specialist notes (GI, nephrology, surgery)
- prescription and dose history for Zepbound
- documentation showing symptoms persisted after stopping
➡️ Evidence checklist: Medical Records
Potential Compensation in Zepbound Lawsuits
Depending on severity and documentation, compensation may address:
- medical bills, hospitalizations, and ER care
- diagnostic tests and specialist treatment
- surgery costs (gallbladder removal, feeding interventions)
- kidney-related treatment, including dialysis
- long-term medication and follow-up care
- lost wages and reduced earning capacity
- disability, pain, suffering, and emotional distress
- diminished quality of life
➡️ More: Compensation
Timeline & Causation Factors Considered
Reviews commonly look at:
- symptom onset after starting Zepbound
- symptom escalation after dose changes
- persistence of symptoms after stopping
- objective diagnostics confirming injury
- length of hospitalization and follow-up impairment
These details help establish whether the medication likely contributed to the injury pattern.
When to Seek Medical & Legal Help
Consider urgent medical care and legal evaluation if you experienced:
- persistent vomiting or inability to keep fluids down
- severe abdominal pain
- dehydration requiring IV fluids
- reduced urination or swelling
- diagnosis of gastroparesis, pancreatitis, bowel obstruction, kidney injury, or gallbladder disease
- surgery (especially gallbladder removal)
- ongoing inability to eat normally months after stopping
How to Start a Zepbound Claim Review
To begin, you generally need to share:
- your Zepbound use timeline (start/stop, dose pattern)
- your main symptoms or diagnosis
- medical care received (ER, hospitalization, surgery)
- whether your condition is ongoing
➡️ Start your review: File a Claim
➡️ Check criteria: Criteria